Research
The line where a peptide becomes a biologic
Federal law draws a size line through the middle of this market. On one side a product is an ordinary drug, and on the other it needs a biologics license, and the line moved in 2019.
Two pathways, one boundary
A medicine reaches the American market through one of two doors. Most are approved as drugs. A smaller set are licensed as biological products, under a different statute with a different application.
Which door a peptide goes through is not a matter of style or marketing. It is decided by a definition, and the definition has a number in it.
The statute lists what counts as a biological product. The list is a series of nouns: a virus, a therapeutic serum, a toxin, an antitoxin, a vaccine, blood or a blood component, an allergenic product, "protein, or analogous product," and some arsenic compounds.
Everything for a peptide seller turns on the word protein, and on where the rules say a peptide stops and a protein starts.
Forty amino acids
The regulation defines the term, and the definition is a single measurable threshold.
A protein "is any alpha amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size."
The definition then handles the obvious edge case. Where two or more amino acid chains are associated with each other "in a manner that occurs in nature," the size is the total across those chains.
The regulation says that total "will not be limited to the number of amino acids in a contiguous sequence." So a two-chain molecule is measured whole, not by its longest single run.
The words that were struck out
For most of the last fifteen years, the definition carried an exception that changed the answer for synthetic products, and it is no longer there.
From 2010 the statute read "protein (except any chemically synthesized polypeptide)". A product built by chemical synthesis was therefore outside the definition, whatever its length.
The Code records the change in its own amendment notes. One reads: Pub. L. 116-94, §605, "struck out" that parenthetical after the word protein.
The operative text today has no such exception in it. Route of manufacture no longer decides the category, and size does. A product made entirely by synthesis can be a biological product if it is long enough.
Why the change was not cosmetic
Removing a parenthetical moved a set of existing products from one regulatory pathway to the other, and it did so on a schedule written into the law.
The Code carries the mechanism. An approved drug application for a biological product "shall be deemed to be a license for the biological product" under the biologics section, on a date the statute fixes.
Later provisions in the same section then work out how exclusivity periods and reference-product rules apply to an application that was deemed a license rather than granted as one.
The practical consequence for a buyer is about which rulebook a product sits under. Licensure, lot release, labeling and the route by which a competitor may copy it all differ between the two pathways.
What the definition does not do
The threshold answers one question and leaves several open, which is worth stating plainly.
It is not a statement about safety, and it is not a statement about effect. A shorter chain is not safer than a longer one, and nothing in the definition suggests otherwise.
The definition also requires "a specific, defined sequence." An undefined mixture is not a protein under this paragraph, which is a separate reason for caring whether a seller publishes a sequence at all.
And the whole definition is conditioned on purpose. Every item on the statutory list has to be "applicable to the prevention, treatment, or cure of a disease or condition of human beings" before it counts.
Where this shows up on a product page
Almost nothing about this is stated on a seller's site, which is why the rule is more useful than the marketing.
A published amino acid sequence is the only thing that lets a reader apply the threshold at all. Sellers who print a sequence have made a checkable statement; sellers who print only a name have not.
Counting is left to the sequence itself, and this site does not count residues on a seller's behalf. What it can say is which side of the line a product would fall on depends on that sequence and nothing else.
Long products also change what a competitor has to do. Copying a licensed biological product runs through the biosimilar route, which is a different exercise from making a generic drug, and that shapes what a market looks like years later.
Reading the definition without over-reading it
Three cautions keep this from being misapplied, and each has bitten someone.
The struck parenthetical still appears in the published text of the section, inside its amendment notes. Finding those words in the document is not the same as finding them in the law, and the operative definition is the one at the top.
A size threshold is not a licensing status. A product being long enough to meet the protein definition says what pathway applies. It does not say the product has a license, and it certainly does not say it has been reviewed.
And a product marketed as a peptide is not automatically short. The word peptide is commercial vocabulary, while the threshold is a count, and only the sequence reconciles the two.
Key takeaways
- Federal law sends medicines through either the drug pathway or the biological product pathway.
- A protein is defined as an amino acid polymer with a defined sequence greater than 40 amino acids.
- Multi-chain molecules associated in a manner that occurs in nature are measured as a total.
- The exception for chemically synthesized polypeptides was struck out and is no longer in the law.
- That struck phrase still appears in the section's amendment notes, and is not the operative text.
- The threshold decides a pathway. It is not a statement about safety, quality or effect.
- Only a published amino acid sequence lets a reader apply the threshold to a product.
Frequently asked questions
What makes something a biological product rather than a drug?
A statutory definition. It lists a virus, therapeutic serum, toxin, antitoxin, vaccine, blood or blood component or derivative, allergenic product, protein or analogous product, and certain arsenic compounds. All of them have to be applicable to the prevention, treatment or cure of a disease or condition of human beings. For this market the operative word is protein, and the regulation supplies the measurement that decides when a chain of amino acids counts as one.
Where exactly is the size line?
The regulation defines a protein as any alpha amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size. It also addresses molecules with more than one chain. Where chains are associated with each other in a manner that occurs in nature, the size is the total across those chains. It is not limited to the number of amino acids in a contiguous sequence. So a multi-chain molecule is measured as a whole.
Does making a peptide synthetically keep it out of the biologic category?
Not any more. The statute used to read "protein (except any chemically synthesized polypeptide)", which put synthetic products outside the definition regardless of length. The Code's own amendment notes record that this parenthetical was struck out. The current operative text contains no such exception, so a chemically synthesized polypeptide long enough to meet the protein definition is a biological product.
Does the definition say anything about whether a peptide is safe?
No. It is a category test, not a safety judgment. Being under the threshold does not make a product safer, better studied or better made, and being over it does not make a product dangerous. What the threshold changes is which approval pathway applies, which application had to be filed, and how a competing version could later be brought to market.
Can I tell which side of the line a product is on?
Only if the seller publishes an amino acid sequence, because the threshold is a count of that sequence. A product name settles nothing, since peptide is commercial vocabulary rather than a defined size. This site does not count residues on a seller's behalf or assign any compound to a side of the line. What it can tell you is that a page printing only a name has not given you what you would need to check.
Why does the pathway matter to a buyer at all?
Because the two pathways carry different requirements and different competitive futures. Products licensed as biological products go through licensure rather than drug approval, and a competitor wanting to sell an equivalent has to use the biosimilar route rather than the generic one. The statute also has machinery for approved drug applications that were deemed to be licenses when the definition changed, and those provisions work out how exclusivity carries across.
Sources
Each document below is named as it names itself, with the date printed on that document rather than the day it was read.
- Title 42 United States Code section 262, Regulation of biological products — the definition of "biological product" at subsection (i)(1), the deemed-license provisions, and the amendment note recording that Public Law 116-94 section 605 struck out the parenthetical excepting any chemically synthesized polypeptide; published with the currency line "Text contains those laws in effect on September 5, 2026" — Office of the Law Revision Counsel, U.S. House of Representatives, September 2026
- Title 21 Code of Federal Regulations section 600.3, Definitions — the definition of biological product at (h), and the definition of a protein at (h)(6) as any alpha amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size, including the treatment of associated chains — Electronic Code of Federal Regulations, Office of the Federal Register, February 2020